Universiteit Leiden
The Netherlands

Exploring the Mycobacterium tuberculosis antigenome: New insights for the development of vaccines, diagnostics and drugs
Coppola, M.

CHAPTER 5

Differences in IgG responses against infection phase related *Mycobacterium tuberculosis* (*Mtb*) specific antigens in individuals exposed or not to *Mtb* correlate with control of TB infection and progression

Mariateresa Coppola[1], Leonar Arroyo[2], Krista E van Meijgaarden[1], Kees LMC Franken[1], Annemieke Geluk[1], Luis F Barrera [2] and Tom HM Ottenhoff [1]

[1] Dept. of Infectious Diseases, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands;
[2] Grupo de Inmunología Cellular e Inmunogenética (GICIG), Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.

ABSTRACT

Tuberculosis (TB) occurs in only 3-10% of *Mycobacterium tuberculosis* (*Mtb*) infected individuals, suggesting that natural immunity can contain *Mtb* infection, although this remains poorly understood. Next to T-cells, a potentially protective role for B-cells and antibodies has emerged recently. However, the *Mtb* antigens involved remain ill-defined. Here, we investigated in a TB-endemic setting IgG levels against 15 *Mtb* antigens, representing various phases of *Mtb* infection and known to be potent human T-cell antigens. IgG levels against ESAT6/CFP10, Rv0440, Rv0867c, Rv1737c, Rv2029c, Rv2215, Rv2389c, Rv3616c and *Mtb* purified protein derivative (PPD) were higher in TB patients than in endemic and non-endemic controls. The only exception was Rv1733c that was preferentially recognized by antibodies from endemic controls compared to TB patients and non-endemic controls, suggesting a potential correlation with control of TB infection and progression. In patients, IgG levels against Ag85B and Rv2029c correlated with *Mtb* loads, while immunoglobulins against Rv0440 differed between genders. Our results support the potential role of certain *Mtb* antigen-(Rv1733c) specific antibodies in the control of TB infection and progression, while other *Mtb* antigen-specific antibodies correlate with TB disease activity and bacillary loads. The findings for Rv1733c agree with previous T-cell results and have implications for including antibody-mediated immunity in designing new strategies to control TB.

INTRODUCTION

Humoral immunity has been generally considered not to play a significant role in controlling infection by *Mycobacterium tuberculosis* (*Mtb*) (1), the facultative intracellular bacillus causing tuberculosis (TB), which causes 1.8 million deaths annually (2). The dominant T-cell-centric paradigm in TB is in line with the classical view of a strict separation between antibody-mediated and cell-mediated immunity directed against extracellular and intracellular pathogens, respectively (3). The elevated susceptibility to *Mtb* in individuals with primary (genetic) or acquired (HIV) cellular immunodeficiencies (4;5) and the strong correlation of polyfunctional CD4+ T cells with TB vaccine-induced protection in mice (6) have contributed to that dogma. As a consequence, our understanding of acquired immunity against TB and corresponding strategies for the development of new candidate TB vaccines have mainly focused on T cell responses (7). However, it is now clear that the presence of *Mtb* specific polyfunctional T cells is not sufficient to protect the human host against TB (8). Moreover, a recent clinical trial revealed that the frequency of polyfunctional T-cells in BCG / MVA85 vaccinated individuals did not correlate with the presence -or absence- of later development of TB disease in children (9;10).

In search of a better understanding of the complex immune response against *Mtb*, several studies have evaluated B cells (11) and immunoglobulin (Ig) responses in the context of *Mtb* infection (12). Whereas the role of B cells is becoming increasingly appreciated (13;14), the contribution of humoral immunity in TB host defence is under debate, although many serological studies have reported the presence of antibodies during *Mtb* infection (15). IgG titres against *Mtb*-specific proteins are detectable in immunocompetent, latently *Mtb*-infected individuals as well as during progression of active *Mtb* infection in TB-asymptomatic smear-negative HIV-positive patients (16). Additionally, a strong correlation has been documented between the presence of specific anti-*Mtb* lipoarabinomannan IgG responses and the absence of miliary TB in a paediatric population, suggesting the possible involvement of specific IgG in containing *Mtb* infection in infants (17). This hypothesis has been further supported by evidence that passive immunization with serum obtained from mice immunized with RUTI, a therapeutic TB vaccine, limited the presence of the bacilli to the lungs of *Mtb*-infected severe combined immunodeficient mice (18). Furthermore, many studies observed that several *Mtb* antigens able to confer TB protection in mice and non-human primates elicited specific mycobacterial antibodies not induced by natural *Mtb* infection (19-21). In addition, the potential protective role of antibody responses has also been suggested by the association of Ag85A-specific IgG boosted by MVA85A vaccination in adolescents with a significantly reduced risk of developing TB (22).

5

Collectively, these results suggest a potential contribution of *Mtb* antigen specific antibodies to protection from TB disease. Various mechanisms may be involved (23), which include: opsonization, which may increase *Mtb* uptake and intracellular killing (24); amelioration of T-cell activation, through an increased secretion of pro-inflammatory cytokines (24); enhanced antigen presentation to CD4 T cells (25); activation of the complement cascade (7); the formation of immune complexes that target *Mtb* antigens and activate DCs through FcR ligation (26); the glycosylation of the constant (Fc) domains that control the balance between pro- and anti-inflammatory antimicrobial responses (27) via up-regulated Fcγ receptor expression (28) by dendritic cells and macrophages (29); the initiation of innate immune signalling through the activation of intracellular receptors such as TRIM21 (30).

In search of better TB diagnostics and new TB vaccine candidates, many innovative strategies have been applied to discover the *Mtb* antigenome responsible for eliciting human cellular immunity (31). *Mtb* dormancy regulon (DosR regulon) encoded proteins as well as resuscitation promoting factor (Rpf) proteins have been associated with *Mtb* latency and found to be recognized by CD4+ and CD8+ T-cells in *Mtb*-infected individuals. Genome-wide unbiased antigen discovery approaches used pulmonary *in vivo Mtb* gene expression profiles in mice infected with *Mtb*, to identify IVE-TB antigens, stimulating T-cell responses in latently *Mtb*-infected individuals (32;33). While all these groups of antigens have been extensively evaluated for their ability to induce T cell responses across many different human populations, these studies were often not complemented by serological analyses. Therefore, we decided to evaluate IgG responses against PPD and a selection of specific *Mtb* antigens, based on our previous antigen discovery work. The antigens studied here included: *Mtb* DosR regulon-encoded proteins (Rv1733c, Rv1737c and Rv2029c) (34), *Mtb* resuscitation-promoting factors (Rv0867c and Rv2389) (35), IVE-TB antigens (Rv0440, Rv0645c, Rv1980c, Rv2031, Rv2215, Rv2626c, Rv3407 and Rv3616c) (33) and *Mtb* antigens related to active growth (ESAT6/CFP10 and Ag85B) (36;37).

MATERIALS AND METHODS

Study design and sample collection. A total of 116 stored samples collected between 2005 and 2014 were used in the present study; these were obtained from the University of Antioquia and included subjects previously recruited in Medellin, Colombia. Individuals were either smear-positive patients experiencing active pulmonary tuberculosis (TB; n = 85: 77 patients had no or <1-month anti-TB chemotherapy, 7 patients 1-2 months of treatment, and 1 patient > 3 months) or healthy individuals from the same endemic area with known (n = 15) or unknown TB

(n = 16) exposure. Humoral responses in these two endemic groups did not differ significantly such that these were combined into a single endemic control group (EC; n = 31). Sera from a group of non-endemic Dutch controls (NEC; n = 25) were included in the study. The Dutch controls were individuals with a negative Mantoux tuberculin skin test (TST) (<15 mm) and QuantiFeron-TB Gold In–Tube test (QFT-GIT) (Cellestis, Carnegie, VIC, Australia) (≤0.3 IU/ml). None of the donors included in this study had comorbidities (HIV-infection, diabetes or cancer) at the time of recruitment.

The study protocols P207/99 and P07/048 were approved by the institutional review board of Leiden University Medical Center, The Netherlands, and by the Ethics Committee of the Instituto de Investigaciones Médicas of the Facultad de Medicina, Universidad de Antioquia. Medellín, Colombia and the local Colombian health authorities (Dirección Seccional de Salud de Antioquia and the Secretaría de Salud de Medellín), respectively.

Mycobacterial stimuli. *Mtb* DosR regulon-encoded proteins (Rv1733c, Rv1737c and Rv2029c), resuscitation-promoting factors (Rv0867c and Rv2389), IVE-TB antigens (Rv0440, Rv0645c, Rv1980c, Rv2031c, Rv2215, Rv2626c, Rv3407 and Rv3616c) and *Mtb* active growth phase antigens (ESAT6/CFP10 fusion protein and Ag85B) were used in this study. HPV16E6 was included as a negative recombinant control. Recombinant production and quality control were performed as previously described (33). *Mtb* purified protein derivative (PPD) RT-50 (Statens Serum Institute, Copenhagen, Denmark) was also included in the screening.

Quantitation of serum IgG antibody responses. Total IgG responses were measured by ELISA (21). Microlon® high binding 96-well plates were coated for two hours at 37°C with PPD, recombinant proteins (5 µg/ml) or PBS 0.4% Bovine Serum Albumin (BSA) used as blank. After removing unbound proteins using washing buffer (PBS containing 0.05% Tween-20), plates were blocked for an hour at 37°C with blocking buffer (PBS containing 1% BSA and 1% Tween-20). After washing plates three times, diluted samples (1:400) were added to the wells and incubated overnight at 4°C. Then, plates were rinsed six times with washing buffer and incubated with polyclonal rabbit anti-human total IgG/HRP (P0214 Dako, Glostrup, Denmark). After two hours at 37°C, plates were washed four times, and tetramethylbenzidine substrate (TMB; Sigma) was added and incubated for 15 minutes in the dark at room temperature. By adding H_2SO_4, the reaction was stopped, and absorbance was measured using a BioRad Microplate Reader 680 (BioRad Laboratories, Veenendaal, The Netherlands) at 450 nm. The blank median optical density (OD450), which ranged 0.05–0.11 in TB, 0.05–0.07 in the EC and 0.05–0.08 in the NEC, was subtracted for each sample to avoid background influence.

Statistical analysis. Statistical analysis was performed using GraphPad Prism (version 6.0). The Mann–Whitney test was used to compare the difference between groups of donors based on the IgG antibody levels measured as OD450 induced by stimulation with the antigens or PPD. A p value less than 0.05 was considered statistically significant.

RESULTS

Differences in *Mtb* specific IgG responses to infection phase related *Mtb* specific protein antigens in subjects exposed or not to *Mtb*

IgG levels against 15 *Mtb* recombinant protein antigens, previously shown to induce significant T cell responses in latently TB infected individuals (LTBI) were measured in 141 sera by ELISA. *Mtb* PPD was used as a positive control antigen. Sera were obtained from Colombian patients with active (pulmonary) tuberculosis (TB) (n = 85), Colombian endemic controls (EC) (n = 31) and Dutch non-endemic controls (NEC) (n = 25) (Table 1). Differences among donor groups were evaluated by the Mann–Whitney test.

Combining the IgG levels against the phase related *Mtb* specific protein antigens, TB patients showed a higher humoral response than EC and NEC (p = 0.0378 and < 0.0001, respectively). A significant difference (p = 0.0015) was also observed between the total levels of antibodies produced by EC and NEC (Figure 1A). A highly significant difference was observed in anti-tuberculin IgG antibody levels between

Table 1. Characteristics of the patients and healthy controls included in the study.

Characteristics	TB patients (n=85)	EC (n=31)	NEC (n=25)
Median age (range)	34 (16-73)	29 (19-65)	38 (27-62)
Male sex	44/85	12/31	8/25
Presence of BCG scar	64/85	12/14	2/25
Sputum smear results:			
1-5 bacilli	28	-	-
5-10 bacilli	23	-	-
>10 bacilli	34	-	-
Median days of treatment (range)	9 (0-155)	-	-
TB recurrences	14	-	-
TST positive	-	8/8	0/16

TB: Tuberculosis; EC: endemic controls; NEC: non-endemic controls; BCG: Bacillus Calmette Guérin; TST: tuberculin skin test.

Figure 1. Cumulative IgG responses to *Mycobacterium tuberculosis* (*Mtb*) antigens. Box-and-whisker plots feature individual dots that correspond to the optical density (OD) values measured in response to all 15 *Mtb* antigens included in this study (A) and PPD (B). Values are shown for sera from 85 TB patients (TB), 31 endemic controls (EC) and 25 non-endemic controls (NEC). The background was subtracted from all samples. A p-value of ≤0.05 was considered significant. Significance levels are indicated as follows: *: p = 0.01–0.05; **: p = 0.001–0.01; ***: p = 0.0001–0.001; ****: p ≤ 0.0001.

TB patients and EC (p < 0.0001), between TB patients and NEC (p < 0.0001), and between EC and NEC (p < 0.0017) (Figure 1B).

Similarly, high serum levels of anti-ESAT6/CFP10 IgG antibodies were found in TB patients compared to EC (p < 0.0001) and NEC (p < 0.0001) (Figure 2A). However, no differences were found between EC and NEC, suggesting that the observed differences in PPD specific IgG between EC and NEC might be due to exposure to non-tuberculous, cross-reactive mycobacterial antigens, present in PPD but absent from ESAT6/CFP10 protein. Although less significant, the IgG responses detected against Rv3616c resembled the trend described for ESAT6/CFP10 (TB vs. EC: p = 0.0243; TB vs. NEC: p = 0.0340) (Figure 2B). In addition, serum IgG levels against other *Mtb* antigens were found to be higher in TB patients than in EC (Rv0867c) and NEC (Rv0440, Rv1737c, Rv2029c, Rv2215, Rv2389c, Rv3616c) and were also higher in EC than in NEC (Rv0440, Rv1733c, Rv1737c, Rv2389c) (Figure 3). Notably, IgG antibody levels against one latency antigen, Rv1733c, were highest in the EC compared to the TB group and NEC (p < 0.0001) (Figure 2C).

Figure 2. Antibody responses to specific *Mtb* antigens and PPD. Box-and-whisker plots include individual dots that correspond to the optical density (OD) values measured in response to the following antigens: (A) ESAT6/CFP10 (E/C), (B) Rv3616c, (C) Rv1733c, (D) HPV16E6. (A), (B), (C), and (D) show values with background subtracted. Significance differences were evaluated between 85 TB patients (TB), 31 endemic controls (EC) and 25 non-endemic controls (NEC). Significance levels are indicated as follows: *: $p = 0.01–0.05$; **: $p = 0.001–0.01$; ***: $p = 0.0001–0.001$; ****: $p \leq 0.0001$.

This is interesting as T cell responses against Rv1733c are normally higher in LTBI than TB patients, in contrast to ESAT6/CFP10. No differences between the groups were observed in the total IgG levels against HPV16E6, used as unrelated control antigen (Figure 2D), or against the other *Mtb* antigens tested (Ag85B, Rv0645c, Rv2031c, Rv2626c and Rv3407) (Figure 3).

Mtb Stimuli	Between-groups comparison		
	TB vs. NEC	TB vs. EC	EC vs. NEC
PPD			
E/C			
Ag85B			
Rv0440			
Rv0645c			
Rv0867c			
Rv1733c			
Rv1737c			
Rv1980c			
Rv2029c			
Rv2031c			
Rv2215			
Rv2389c			
Rv2626c			
Rv3407			
Rv3616c			

p value
- ≤ 0.0001
- ≤ 0.001
- ≤ 0.01
- ≤ 0.05
- > 0.05

Figure 3. Comparison of specific IgG antibody levels between TB patients, Endemic Controls (EC) and Non-Endemic Controls (NEC). Grey tonality indicates different significant levels of *Mtb* antigen-specific IgG among patients and controls. TB: TB patients; EC: endemic controls; NEC: non-endemic controls. E/C: ESAT6/CFP10.

5

IgG responses to specific *Mtb* antigens differ between TB patients by gender and clinical characteristics

The IgG responses detected within the TB patient group were analysed in more detail with respect to age, gender, evidence of BCG scar and clinical characteristics reported at recruitment (Table 1). Interestingly, IgG levels against Rv0440 were higher in males than in females (p = 0.0193), suggesting a significant influence of gender on the humoral immune response against this antigen (Figure 4A). In addition, individuals with a high number of acid-fast bacilli detected in sputum by smear microscopy (bacilli > 10) tended to have increased levels of IgG antibodies against Rv2029c and Ag85B compared to patients with lower numbers of detectable bacilli (>10 vs. 5–10 bacilli; Rv2029: p = 0.0194; >10 vs. 5–10 bacilli; Ag85B: p = 0.0186; >10 vs 1–5 bacilli; Ag85B: p = 0.0002) (Figure 4B). This was not the case for ESAT6/CFP10 or PPD (Figure 4). Moreover, TB cases with an actual recurrence episode had higher levels of IgG to ESAT6/CFP10 and Rv3616c than the cases experiencing the first episode of pulmonary TB (ESAT6/CFP10: p = 0.0177; Rv3616c: p = 0.0481) (Figure 4C). Age, days of treatment and presence of BCG scar did not appear to have any influence on specific IgG levels.

Figure 4. Antibody responses to specific *Mtb* antigens in TB patients with diverse demographic and clinical characteristics. (A) Box-and-whisker plots include individual dots that correspond to the optical density (OD) values measured in response to the following antigens: Rv0440, ESAT6/CFP10 (E/C), and PPD, in male and female TB patients.

(B) Box-and-whisker plots include individual dots that correspond to the optical density (OD) values measured in response to the following antigens: Ag85B, Rv2029c, ESAT6/CFP10 (E/C), and PPD, in TB patient with low (1-5 bacilli), intermidiate (5-10 bacilli) and high (>10 bacilli) bacterial load.

Continue

(C) Box-and-whisker plots include individual dots that correspond to the optical density (OD) values measured in response to the following antigens: ESAT6/CFP10 (E/C), Rv3616c, and PPD, in TB cases with recurrent (TB recurrent) or new diagnosed disease (newTB). Significance levels were indicated as follows: *: $p = 0.01–0.05$; **: $p = 0.001–0.01$; ***: $p = 0.0001–0.001$; ****: $p \leq 0.0001$.

DISCUSSION

Although the role of humoral immunity in tuberculosis (TB) is widely debated, an increasing number of studies has proposed B cells and antibodies as significant components of the immune response against *Mycobacterium tuberculosis* (*Mtb*) (11;23). The improved containment of TB through passive transfer of immune polyclonal sera in mice (18), the treatment of TB in a mouse model by monoclonal immunoglobulins (38), the increased TB susceptibility in human hosts with antibody deficits (17), the association of *Mtb* antigen directed antibody titres with reduced *Mtb* loads in animals (19-21) and with reduced TB risk in BCG/MVA85A vaccinated infants (22), and the expansion of *in vitro* studies suggesting a microbicidal role of certain PPD directed antibodies (24;27) all tend to lend support to the hypothesis that humoral-mediated immunity might contribute to an overall protective response to *Mtb*.

As mentioned above, many *Mtb* antigens have been discovered by different strategies (39) focusing on analysing T cell responses, but these studies rarely included antigen recognition by antibodies. We therefore decided to investigate the presence of IgG antibodies against 15 *Mtb* antigens representing different stages of *Mtb* infection: ESAT6/CFP10 and Ag85B generally representing the active *Mtb* replication stage (36;37); Rv1733c, Rv1737c and Rv2029c, representing *Mtb* DosR regulon-encoded proteins (34); Rv0867c and Rv2389, two resuscitation-promoting factors, expressed during *Mtb* reactivation (35); Rv0440, Rv0645c, Rv1980c, Rv2031, Rv2215, Rv2626c, Rv3407 and Rv3616c which genes are up-regulated during *in vivo Mtb* pulmonary infection in mice (33).

As described in other studies (40;41), *Mtb* specific antibody levels were significantly higher in TB patients than in EC and NEC. The IgG response to each *Mtb* antigen mostly followed the trend of higher IgG levels correlating with higher *Mtb* exposure. To our knowledge, five antigens (Rv0645, Rv2215, Rv2626c, Rv3407 and Rv3616c) were studied here for the first time in the context of humoral TB immunity. The other *Mtb* stimuli (PPD, ESAT6/CFP10, Ag85B, Rv0440, Rv0867c, Rv1733c, Rv1737c, Rv1980c, Rv2029c, Rv2031c and Rv2389c) have been evaluated in other serological studies (40-46), which also showed higher IgG antibody levels against specific antigens in TB patients than in the control groups. Out of the 15 *Mtb* phase related antigens screened, nine showed a different humoral profile between the groups analysed. Except for one (Rv2215), all the antigens recognized by antibodies are known to be secreted proteins or to have predicted transmembrane regions (according to TubercuList: http://tuberculist.epfl.ch/). IgGs against two (Rv2215 and Rv3616c) out of the five antigens that were originally included here were also

increased in TB patients compared to controls. Our results for ESAT6/CFP10 and Rv0867c are in agreement with previous reports (40;42;44;46). Although for Rv2029c, Rv1737c and Rv2389c we could not confirm a significant difference between the antibody levels in TB patients and EC, as recently observed in a Brazilian cohort (46), we nevertheless found increased IgG antibody levels in TB compared with NEC. While controversial results have already been reported on the humoral response against Ag85B and Rv1980c (15;40-43), IgG antibodies against Rv2031c have been mostly described to be increased in TB patients (15;42;44;45). In line with some of these studies but in contrast to others, Rv1980c-, Rv2031c- and Ag85B-specific IgG levels did not show any differences between the groups in our cohort. The slightly different serological antigen recognition profile we find compared to other studies is not surprising. Variation in antibody responses has already been extensively discussed previously, and has been ascribed to multiple factors, including the different immunogenetic backgrounds of infected hosts; the expression and production of diverse mycobacterial antigens during multiple stages of *Mtb* infection; different antigen recognition patterns in different individuals by genetically restricted T helper cells, which contribute to the induction of antibodies (42), as well as microbiota- and NTM-exposure related factors. Moreover, polymorphisms that might occur in B cell epitopes regions (23) could also contribute to the wide variability found here and in other reports. This has been suggested for Rv1980 by two studies (47;48), which showed a high rate of mutations affecting the B cell epitopes repertoire of that antigen in clinical isolates.

Interestingly, the only exception was antigen Rv1733c to which specific IgG antibody levels were found to be significantly higher in EC than in both TB patients and NEC. The EC group is likely to have been exposed to *Mtb* in the past, (36) and the pattern of IgG levels agrees well with the T cell signature that has repeatedly been observed against this latency antigen: Rv1733c is preferentially recognized by T cells from LTBI individuals compared to TB patients in both EU, African, South American populations as well as in India (unpublished) (34;35). In other work we have also shown that NTM can induce higher IFN-ɣ response against Rv1733c in NTM-exposed donors than in unexposed controls (49). Therefore, it was not unexpected to find increased anti-Rv1733 IgGs in the EC group considering the endemic setting of the study population where both *Mtb* and NTM are present. In any case, the higher levels of Rv1733c antibodies and the difference found between the EC and the other groups are relevant as this data suggest Rv1733c specific antibodies levels are associated with control of TB infection and progression. We have also found high titres of antibodies in HLA-DR3 transgenic mice after immunisation with a multistage-polyepitope vaccine containing a Rv1733c epitope, or with a long synthetic peptide both derived from Rv1733c (20;21). To our knowledge, only one other study has

evaluated the anti-Rv1733 IgG in another endemic cohort (46), however, this did not reveal the same trend as we describe here. The different outcome could be attributed to the different IgG isotypes analysed (IgG1 vs. total IgG), the different readout used (ELISA index vs. OD450), differences in study populations and differences in infection levels. Our observations provide a lead towards further studies addressing the precise role of Rv1733c specific antibodies in TB infection.

Of note, the levels of antibodies measured were higher for PPD and ESAT6/CFP10 than for any other *Mtb* antigen. As discussed for other pathogens (50), however, more might not be necessarily better in qualitative terms: higher levels of antibodies could be paradoxically less protective than lower levels, contributing to the so-called 'prozone-like effect.' For TB, the high levels of anti-tuberculin IgG found not only in TB patients but also in high-risk TB contacts is in line with such a theory (51;52): in contrast to donors with low tuberculin antibody titres, sera from individuals with high PPD-IgG titres were found to modulate the proliferative activity of the PBMCs of autologous donors either by increasing or blocking PBMC stimulation. Additionally, it has been found previously that in active TB disease the expression of the high-affinity IgG receptor (FCGR1A) is higher than in LTBI, which could suggest a significant contribution of antibodies to TB pathogenesis (28).

Although the size of the groups compared in the present study was relatively small, cases with recurrent TB had higher levels of antibodies against ESAT6/CFP10 and Rv3616c, while antibody levels against Ag85B and Rv2029c were associated with bacterial load at the time of recruitment, confirming a trend reported previously (44). Examining the correlation of clinical information with the antibody production in the TB group, we also found that anti-Rv0440 IgG levels differed according to gender, confirming the trend in a previous study in which the levels of antibodies against a set of *Mtb*-specific antigens were higher in males than in females (53). This result could be influenced also by other factors, such as an increased antigen load due to a more severe disease in one of the two groups. This effect could not be assessed due to a lack of information regarding the disease severity of the patients enrolled. Antibodies against Rv0440 have also been observed in other pathological conditions such as in the progression of inflammatory (55) and autoimmune diseases (56). For instance, IgG against Rv0440 has been suggested to be protective against adjuvant-induced arthritis, whose related human pathology is more frequent in females than males (57). Underlying gender-dependent pathogenic and pathophysiological processes could be of broader relevance to other diseases as well.

Our study had several limitations. First of all, the small size of the groups limits the impact of our conclusions, especially on the demographic parameters. We

could not evaluate the impact of helminth infection on the measured IgG levels, although that condition is recognized to affect either humoral or cellular immunity to *Mtb* (58). Moreover, we investigated only the total amount of IgG antibodies against specific *Mtb* antigens but not the contribution of each IgG isotype, the antibody avidity or the different glycosylation patterns present in the Fc portion of the immunoglobulins detected (12;27), which could have given more insights into the antibody's functionality.

In conclusion, our collective findings support the need to further investigate and understand the pleiotropic effect of antibodies in the immune response to *Mtb*, their influence on TB disease outcome and their possible contribution to control *Mtb* infection.

ACKNOWLEDGEMENT

CONFLICT OF INTERESTS

The authors report no conflict of interests.

REFERENCES

1. Glatman-Freedman A. The role of antibody-mediated immunity in defense against *Mycobacterium tuberculosis*: advances toward a novel vaccine strategy. Tuberculosis (Edinb) 2006 May;86(3-4):191-7.
2. WHO. Global tuberculosis report 2016. Geneva: World Health Organization. 2016.
3. Casadevall A. To Be or Not Be a (Functional) Antibody Against TB. Cell 2016 Oct 6;167(2):306-7.
4. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002 Sep;32(1):97-105.
5. Ronacher K, Joosten SA, van CR, Dockrell HM, Walzl G, Ottenhoff TH. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev 2015 Mar;264(1):121-37.
6. Lindenstrom T, Agger EM, Korsholm KS, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009 Jun 15;182(12):8047-55.
7. Abebe F, Bjune G. The protective role of antibody responses during *Mycobacterium tuberculosis* infection. Clin Exp Immunol 2009 Aug;157(2):235-43.
8. Caccamo N, Guggino G, Joosten SA, et al. Multifunctional CD4(+) T cells correlate with active *Mycobacterium tuberculosis* infection. Eur J Immunol 2010 Aug;40(8):2211-20.
9. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010 Oct 15;182(8):1073-9.
10. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013 Mar 23;381(9871):1021-8.
11. Achkar JM, Chan J, Casadevall A. B cells and antibodies in the defense against *Mycobacterium tuberculosis* infection. Immunol Rev 2015 Mar;264(1):167-81.
12. Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 2013 Mar 13;13(3):250-62.
13. Joosten SA, van Meijgaarden KE, Del NF, et al. Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. PLoS Pathog 2016 Jun;12(6):e1005687.
14. Phuah J, Wong EA, Gideon HP, et al. Effects of B Cell Depletion on Early *Mycobacterium tuberculosis* Infection in Cynomolgus Macaques. Infect Immun 2016 May;84(5):1301-11.
15. Steingart KR, Dendukuri N, Henry M, et al. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol 2009 Feb;16(2):260-76.
16. Siev M, Wilson D, Kainth S, et al. Antibodies against Mycobacterial proteins as biomarkers for HIV-associated smear-negative tuberculosis. Clin Vaccine Immunol 2014 Jun;21(6):791-8.
17. Costello AM, Kumar A, Narayan V, et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans R Soc Trop Med Hyg 1992 Nov;86(6):686-92.
18. Guirado E, Amat I, Gil O, et al. Passive serum therapy with polyclonal antibodies against *Mycobacterium tuberculosis* protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 2006 Apr;8(5):1252-9.
19. Langermans JA, Doherty TM, Vervenne RA, et al. Protection of macaques against *Mycobacterium tuberculosis* infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005 Apr 15;23(21):2740-50.

5

20. Geluk A, van den Eeden SJ, van Meijgaarden KE, Dijkman K, Franken KL, Ottenhoff TH. A multistage-polyepitope vaccine protects against *Mycobacterium tuberculosis* infection in HLA-DR3 transgenic mice. Vaccine 2012 Dec 14;30(52):7513-21.

21. Coppola M, van den Eeden SJ, Wilson L, Franken KL, Ottenhoff TH, Geluk A. Synthetic Long Peptide Derived from *Mycobacterium tuberculosis* Latency Antigen Rv1733c Protects against Tuberculosis. Clin Vaccine Immunol 2015 Sep;22(9):1060-9.

22. Fletcher HA, Snowden MA, Landry B, et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun 2016; 7:11290.

23. Jacobs AJ, Mongkolsapaya J, Screaton GR, McShane H, Wilkinson RJ. Antibodies and tuberculosis. Tuberculosis (Edinb) 2016 Dec;101:102-13.

24. de VS, Abate G, Blazevic A, Heuertz RM, Hoft DF. Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infect Immun 2005 Oct;73(10):6711-20.

25. Kumar SK, Singh P, Sinha S. Naturally produced opsonizing antibodies restrict the survival of *Mycobacterium tuberculosis* in human macrophages by augmenting phagosome maturation. Open Biol 2015 Dec;5(12):150171.

26. Cliff JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013 Jan 1;207(1):18-29.

27. Lu LL, Chung AW, Rosebrock TR, et al. A Functional Role for Antibodies in Tuberculosis. Cell 2016 Oct 6;167(2):433-43.

28. Sutherland JS, Loxton AG, Haks MC, et al. Differential gene expression of activating Fcgamma receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect 2014 Apr;20(4): O230-O238.

29. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 2014 Feb;14(2):94-108.

30. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 2013 Apr;14(4):327-36.

31. Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH. Innovative Strategies to Identify *M. tuberculosis* Antigens and Epitopes Using Genome-Wide Analyses. Front Immunol 2014;5:256.

32. Commandeur S, van Meijgaarden KE, Prins C, et al. An unbiased genome-wide *Mycobacterium tuberculosis* gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J Immunol 2013 Feb 15;190(4):1659-71.

33. Coppola M, van Meijgaarden KE, Franken KL, et al. New Genome-Wide Algorithm Identifies Novel *In Vivo* Expressed *Mycobacterium tuberculosis* Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles. Sci Rep 2016 Nov 28; 6:37793.

34. Leyten EM, Lin MY, Franken KL, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of *Mycobacterium tuberculosis*. Microbes Infect 2006 Jul;8(8):2052-60.

35. Arroyo L, Rojas M, Franken KL, Ottenhoff TH, Barrera LF. Multifunctional T Cell Response to DosR and Rpf Antigens Is Associated with Protection in Long-Term *Mycobacterium tuberculosis*-Infected Individuals in Colombia. Clin Vaccine Immunol 2016 Oct;23(10):813-24.

36. del CH, Paris SC, Marin ND, et al. IFNgamma response to *Mycobacterium tuberculosis*, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 2009;4(12):e8257.

37. Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011 Feb;17(2):189-94.

38. Teitelbaum R, Glatman-Freedman A, Chen B, et al. A mAb recognizing a surface antigen of *Mycobacterium tuberculosis* enhances host survival. Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15688-93.

39. Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH. Innovative Strategies to Identify *M. tuberculosis* Antigens and Epitopes Using Genome-Wide Analyses. Front Immunol 2014; 5:256.

40. Wu X, Yang Y, Zhang J, et al. Comparison of antibody responses to seventeen antigens from *Mycobacterium tuberculosis*. Clin Chim Acta 2010 Oct 9;411(19-20):1520-8.

41. Senoputra MA, Shiratori B, Hasibuan FM, et al. Diagnostic value of antibody responses to multiple antigens from *Mycobacterium tuberculosis* in active and latent tuberculosis. Diagn Microbiol Infect Dis 2015 Nov;83(3):278-85.

42. Lyashchenko K, Colangeli R, Houde M, Al JH, Menzies D, Gennaro ML. Heterogeneous antibody responses in tuberculosis. Infect Immun 1998 Aug;66(8):3936-40.

43. Weldingh K, Rosenkrands I, Okkels LM, Doherty TM, Andersen P. Assessing the serodiagnostic potential of 35 *Mycobacterium tuberculosis* proteins and identification of four novel serological antigens. J Clin Microbiol 2005 Jan;43(1):57-65.

44. Niki M, Suzukawa M, Akashi S, et al. Evaluation of Humoral Immunity to *Mycobacterium tuberculosis*-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development. J Immunol Res 2015; 2015:527395.

45. Baumann R, Kaempfer S, Chegou NN, et al. Serologic diagnosis of tuberculosis by combining Ig classes against selected mycobacterial targets. J Infect 2014 Dec;69(6):581-9.

46. Mattos AM, Chaves AS, Franken KL, et al. Detection of IgG1 antibodies against *Mycobacterium tuberculosis* DosR and Rpf antigens in tuberculosis patients before and after chemotherapy. Tuberculosis (Edinb) 2016 Jan;96:65-70.

47. Jiang Y, Liu H, Wang H, et al. Polymorphism of antigen MPT64 in *Mycobacterium tuberculosis* strains. J Clin Microbiol 2013 May;51(5):1558-62.

48. Jiang Y, Liu H, Wan K. MPT64 polymorphisms of *Mycobacterium tuberculosis* strains suggest ongoing immune evasion. Tuberculosis (Edinb) 2014 Dec;94(6):712-4.

49. Lin MY, Reddy TB, Arend SM, et al. Cross-reactive immunity to *Mycobacterium tuberculosis* DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria. Infect Immun 2009 Nov;77(11):5071-9.

50. Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol 2003 Apr 1;170(7):3621-30.

51. Encinales L, Zuniga J, Granados-Montiel J, et al. Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis. Mol Immunol 2010 Feb;47(5):1066-73.

52. Feris EJ, Encinales L, Awad C, et al. High levels of anti-tuberculin (IgG) antibodies correlate with the blocking of T-cell proliferation in individuals with high exposure to *Mycobacterium tuberculosis*. Int J Infect Dis 2016 Feb; 43:21-4.

53. Chavez K, Ravindran R, Dehnad A, Khan IH. Gender biased immune-biomarkers in active tuberculosis and correlation of their profiles to efficacy of therapy. Tuberculosis (Edinb) 2016 Jul;99:17-24.

54. Wick G, Perschinka H, Millonig G. Atherosclerosis as an autoimmune disease: an update. Trends Immunol 2001 Dec;22(12):665-9.

55. Huszti Z, Bene L, Kovacs A, et al. Low levels of antibodies against E. coli and mycobacterial 65kDa heat shock proteins in patients with inflammatory bowel disease. Inflamm Res 2004 Oct;53(10):551-5.

56. Dow CT. M. paratuberculosis Heat Shock Protein 65 and Human Diseases: Bridging Infection and Autoimmunity. Autoimmune Dis 2012; 2012:150824.

5

57.   Kim EY, Durai M, Mia Y, Kim HR, Moudgil KD. Modulation of Adjuvant Arthritis by Cellular and Humoral Immunity to Hsp65. Front Immunol 2016; 7:203.

58.   Toulza F, Tsang L, Ottenhoff TH, Brown M, Dockrell HM. *Mycobacterium tuberculosis*-specific CD4+ T-cell response is increased, and Treg cells decreased, in anthelmintic-treated patients with latent TB. Eur J Immunol 2016 Mar;46(3):752-61.

5